RBC Capital raised the firm’s price target on Boston Scientific (BSX) to $98 from $95 and keeps an Outperform rating on the shares. The company’s Q3 results were “impressive”, while the management raised its 2024 guide, now exiting the year at +15% organic sales growth, the analyst tells investors in a research note. The stock was down due to a temporary pause in an EP trial, AVANTGUARD, but the decline appears overdone based on its key opinion leader checks, RBC added.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $110 from $100 at Mizuho
- Boston Scientific price target raised to $100 from $92 at Bernstein
- Boston Scientific price target raised to $98 from $87 at Wells Fargo
- Boston Scientific price target raised to $98 from $92 at Citi
- Boston Scientific (NYSE:BSX) Q3 Earnings Show Significant Sales Growth